BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-713@pharmaconomics
DTSTAMP:20260707T033904Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:DNLI Phase 2 — BIIB122 (estimated date)
DESCRIPTION:Phase 2 trial results for BIIB122 in Parkinson’s disease are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm\n\nTrack it: https://pharmaconomics.com/e/713
URL:https://pharmaconomics.com/e/713
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR